Evidence map›Paper›PMID 40602764›Full record

ArticleAmerican journal of physiology. Renal physiology2025

Kidney organoids demonstrate that PTH1R drives a cystogenic cAMP-pPKA-pCREB axis in developmental polycystic kidney disease.

Humayra Afrin, Jielu Hao Robichaud, Usama Qamar, Peter C Harris, Navin Gupta

Abstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Humayra AfrinDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States.
Jielu Hao RobichaudDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States.
Usama QamarDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States.
Peter C HarrisDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States.
Navin GuptaDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States.ORCID 0009-0003-7005-4098

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Pilot and FeasibilityP30DK090728 · NIDDK · MAYO CLINIC ROCHESTER · PI TORRES, VICENTE E · 2010 to 2019
$11.8M
National Coordinating Center (NCC) for the Polycystic Kidney Disease (PKD) Research and Translation Core CentersU24DK126110 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Terry J Watnick · 2020 to 2026
$7.4M
HHS | NIH | National Center for Advancing Translational Sciences (NCATS) UL1TR002377HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U24DK126110Mayo Clinic (The Mayo Clinic) Penske Career Development AwardNCATS NIH HHS UL1 TR002377NIDDK NIH HHS P30 DK090728NIDDK NIH HHS U24 DK126110
6 · The paper itself

Abstract

Human pluripotent stem cell-derived kidney organoids have demonstrated utility in modeling kidney development and genetic disease. Autosomal recessive polycystic kidney disease (ARPKD) is an inherited developmental cystic kidney disease of high morbidity and mortality that lacks directed therapy. To overcome the limitations of animal models and stimulate drug discovery, ARPKD organoids have previously been subject to well-described cystogenic mechanisms for use in therapeutic screens. Although these studies have validated genotype-phenotype correlations and cystogenic response of ARPKD organoids as similar to existing in vitro models, novel cystogenic mechanisms that expand potential therapeutic targets have yet to be uncovered. Here we use a combination of human induced pluripotent stem cell-derived ARPKD and isogenic wild-type organoids, native kidney and organoid single-cell RNA sequencing, decedent human ARPKD tissue, and targeted mechanistic studies to describe PTH1R as a stimulatory G-protein-coupled receptor, which instigates a cystogenic signaling cascade in developmental cystic kidney disease. Our findings demonstrate the utility of kidney organoids as an in vitro model for pathomechanisms of rare diseases, which lack faithful animal models.

Indexed as

Cyclic AMPKidneyOrganoidsPolycystic Kidney, Autosomal RecessiveReceptor, Parathyroid Hormone, Type 1HumansInduced Pluripotent Stem CellsSignal TransductionCyclic AMPPTH1R protein, humanReceptor, Parathyroid Hormone, Type 1human stem cellkidney organoidpolycystic kidney diseasePTH receptorPTH signaling

Identifiers

PMID40602764
PMCPMC12506767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.